White Papers

Provided By:

WCG

April 26, 2021

Before 2020, most study training provided to clinical research sites relied heavily on monitors doing training at initiation visits, and web-based on-demand training was a novel concept used by only a few forward-thinking sponsors. When the COVID-19 pandemic hit, web-based o … Read More »

Provided By:

WCG IRB

April 12, 2021

Paying participants for the essential role that they play in clinical trials is important, but the amount given, and how it is paid, require careful consideration. Appropriately compensating clinical trial participants lessens the financial burden placed on them by participa … Read More »

Provided By:

TrialCard

April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic … Read More »

Provided By:

Elligo Health Research

April 6, 2021

If identifying and including patients is one of the biggest hurdles of a clinical trial, how does access to 100 million patients sound? This white paper shares how a robust patient database is one critical key that impacts multiple facets of a trial, leading to more successf … Read More »

Provided By:

Clinical Ink

March 26, 2021

The biggest challenge facing clinical research today is the need to gather, analyze, and report data. To collect patient data more efficiently, the industry has turned to electronic patient-reported outcome (ePRO) tools, which allow patients to enter data themselves, most of … Read More »

Provided By:

TrialCard

December 9, 2020

Since the end of the pharmaceutical industry’s “blockbuster era” and the beginning of its “specialty product era”, drug makers have used the term “hub services” to describe the often ponderous process of  ranting patients access to critical medications. While the term itself … Read More »

Provided By:

ArcheMedX

December 8, 2020

Discover what you can do today to firmly establish your competitive advantage – to avoid being relegated to the sidelines. Will 2021 allow us to bid farewell to COVID-19? Whether we can eradicate this terrible virus or not, many of its impacts will persist. To assist Sponsor … Read More »

Provided By:

WCG

November 9, 2020

Targeted expertise when and where you need it: WCG Clinical Research Coordinators help equip sites to navigate the “new normal.”

Provided By:

TrialCard Incorporated

October 29, 2020

As the market landscape relative to co-pay assistance programs continues to evolve, it is important for biopharmaceutical manufacturers to have a practical strategy in place.  This white paper provides valuable insight into planning for 2021 and beyond. TrialCard Incorporate … Read More »

Provided By:

Avant Healthcare

October 27, 2020

The defining medium of our age, social media has revolutionized the way we communicate, learn about the world, and organize ourselves into communities. For doctors and other HCPs, social media presents an unprecedented opportunity for engagement and collaboration that is sha … Read More »

Provided By:

ArcheMedX

October 8, 2020

A deer in the headlights. That’s an easy way to describe most sales leaders right now, as they formulate how they’re going to implement new “virtual selling” sales frameworks with their formerly “press the flesh” sales teams. But really – a year ago – if you’d suggested to m … Read More »

Provided By:

Elligo Health Research

August 14, 2020

As COVID-19 continues to disrupt clinical research, the consequences are poised to be devastating for sponsors, physicians, patients, and worldwide health. Elligo Health Research® is uniquely situated and experienced to support the continuation of effective clinical research … Read More »

Provided By:

Elligo Health Research

August 10, 2020

The disconnect between clinical research and medical care has become increasingly burdensome, especially in the wake of the COVID-19 pandemic. As clinical research sponsors continually seek ways to accelerate their trials while maintaining safety and quality, technology rema … Read More »

Provided By:

WCG

August 5, 2020

Infectious disease “challenge” studies, in which healthy participants are deliberately infected with pathogens to investigate the cause, prevention, and treatment of infectious diseases, hold great potential for delivering high-quality data about new interventions. Infectiou … Read More »

Provided By:

Clinical Ink

May 28, 2020

Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. The biggest challenge facing clinical research today is the need to gather, analyze, and report data. To collect patient data more efficiently, researchers are increasingly explorin … Read More »

Provided By:

TrialCard

March 30, 2020

Affordability programs, like co-pay programs, are highly effective at helping patients initiate therapy by reducing cost barriers. While they also improve fill rates incrementally, affordability programs only address the financial barriers to non-adherence without tackling t … Read More »

Provided By:

81qd

February 26, 2020

Susan  Abedi shares how AI can be a positive disruptor for diagnosis – how to take advantage of  its potential and engage effectively with HCPs and patients to shorten the time to diagnosis. She also covers how AI can raise awareness of the clinical journey. There is also a … Read More »

Provided By:

LexisNexis Risk Solutions

January 31, 2020

The world of medical claims data can be extremely complex. With over 100,000 ICD-10 diagnosis and CPT procedure codes currently in use, to wade through de-identified claims data often rests solely on the expertise of those who can confidently navigate vast amounts of big dat … Read More »

Provided By:

LexisNexis

January 10, 2020

View this informative infographic containing numerous statistics about influenza in the U.S.

Provided By:

Manatt Health

October 15, 2019

To help you manage effectively through the intricacies of 340B, Manatt Health has developed a 50-state survey on 340B, analyzing how states reimburse 340B covered entities and contract pharmacies for 340B drugs, and the steps states are taking to avoid duplicate discounts. D … Read More »

Provided By:

MicroMass Communications

September 26, 2019

“Behavioral science” is becoming a buzzword for pharma. Why? Because behavior is a barrier to meeting brand objectives. This barrier could be in the form of a patient’s adherence, a patient’s reluctance to start a new therapy, or even a healthcare provider’s clinical inertia … Read More »

Provided By:

MedSurvey

August 1, 2019

This white paper provides critical information about obstacles to continued oncology research and recommendations for effectively overcoming them. It first traces current and projected trends in the field of oncology and related market research. Next it presents key findings … Read More »

Provided By:

eClinical Solutions

July 9, 2019

Data from clinical trials is extremely valuable but often underutilized. This is typically the result of insufficient planning. Industry experts are frustrated knowing that stakeholders do not have sufficient access to their data, thus losing tremendous value since the data … Read More »

Provided By:

Avant Healthcare

June 19, 2019

Storytelling may seem like an antiquated tool in modern times, which is exactly what makes it so powerful. How? Life unfolds in the narratives we share with each other. A great story can go where quantitative analysis often cannot: straight to the heart. Clinical trial data … Read More »

Provided By:

HAVAS LYNX GROUP

June 10, 2019

This white paper explores how some of the world’s most innovative companies are bringing the patient experience front and centre in clinical trials, and reaping the benefits of doing so. From protocol design to recruitment and retention, it’s about seeing every touchpoint th … Read More »

Provided By:

PharmaSeek

August 21, 2018

Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dolla … Read More »

FEEDBACK